Cláudia Casanova

1.3k total citations
24 papers, 421 citations indexed

About

Cláudia Casanova is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Cláudia Casanova has authored 24 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Reproductive Medicine. Recurrent topics in Cláudia Casanova's work include Lung Cancer Treatments and Mutations (8 papers), Ovarian cancer diagnosis and treatment (6 papers) and Lung Cancer Research Studies (6 papers). Cláudia Casanova is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Ovarian cancer diagnosis and treatment (6 papers) and Lung Cancer Research Studies (6 papers). Cláudia Casanova collaborates with scholars based in Italy, United Kingdom and Switzerland. Cláudia Casanova's co-authors include Lucio Crinò, Maximilian Papi, Alessandro Gamboni, Claudio Dazzi, Daniele Calistri, Angelo Delmonte, Marita Mariotti, Elisa Chiadini, Laura Capelli and Paola Ulivi and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Cláudia Casanova

21 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Cláudia Casanova Italy	9	273	267	128	100	62	24	421
Alfonso Illiano Italy	7	317 1.2×	299 1.1×	108 0.8×	75 0.8×	43 0.7×	9	469
Yasmine Baca United States	10	174 0.6×	83 0.3×	75 0.6×	94 0.9×	51 0.8×	56	292
Paloma Martín-Martorell Spain	11	279 1.0×	190 0.7×	52 0.4×	82 0.8×	37 0.6×	30	426
Angelika Terbuch Austria	13	172 0.6×	159 0.6×	103 0.8×	149 1.5×	120 1.9×	33	397
Cyril Abdeddaim France	10	302 1.1×	92 0.3×	88 0.7×	77 0.8×	86 1.4×	30	519
T. Giannakakis Greece	13	367 1.3×	90 0.3×	121 0.9×	79 0.8×	68 1.1×	24	457
O. Nascimben Italy	11	173 0.6×	60 0.2×	115 0.9×	118 1.2×	67 1.1×	21	352
Feiyu Niu China	12	266 1.0×	314 1.2×	130 1.0×	175 1.8×	54 0.9×	25	513
Jiewen Peng China	10	206 0.8×	103 0.4×	59 0.5×	53 0.5×	45 0.7×	19	331
Şeyda Gündüz Türkiye	9	185 0.7×	76 0.3×	79 0.6×	31 0.3×	47 0.8×	15	251

Countries citing papers authored by Cláudia Casanova

Since Specialization

Citations

This map shows the geographic impact of Cláudia Casanova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cláudia Casanova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cláudia Casanova more than expected).

Fields of papers citing papers by Cláudia Casanova

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cláudia Casanova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cláudia Casanova. The network helps show where Cláudia Casanova may publish in the future.

Co-authorship network of co-authors of Cláudia Casanova

This figure shows the co-authorship network connecting the top 25 collaborators of Cláudia Casanova. A scholar is included among the top collaborators of Cláudia Casanova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cláudia Casanova. Cláudia Casanova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Farolfi, Alberto, Elisabetta Petracci, Giorgia Gurioli, et al.. (2023). Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients. Frontiers in Oncology. 13. 2 indexed citations

Scambia, Giovanni, Francesco Raspagliesi, Giorgio Valabrega, et al.. (2022). Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).. Journal of Clinical Oncology. 40(17_suppl). LBA5504–LBA5504. 4 indexed citations

Gurioli, Giorgia, Gianluca Tedaldi, Alberto Farolfi, et al.. (2022). Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients. International Journal of Molecular Sciences. 23(24). 15789–15789. 4 indexed citations

Farolfi, Alberto, Emanuela Scarpi, Filippo Greco, et al.. (2020). Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study. Scientific Reports. 10(1). 18190–18190. 21 indexed citations

Farolfi, Alberto, Giorgia Gurioli, Paola Fugazzola, et al.. (2019). Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches. International Journal of Molecular Sciences. 20(10). 2569–2569. 19 indexed citations

Farolfi, Alberto, Micaela Petrone, Emanuela Scarpi, et al.. (2018). Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24). Targeted Oncology. 13(4). 469–479. 43 indexed citations

Chiadini, Elisa, Matteo Canale, Angelo Delmonte, et al.. (2018). Frequency of actionable alterations in epidermal growth factor receptor (EGFR) wild type non-small cell lung cancer: experience of the Wide Catchment Area of Romagna (AVR). Journal of Thoracic Disease. 10(8). 4858–4864. 2 indexed citations

Dazzi, Claudio, Alessandro Gamboni, Angelo Delmonte, et al.. (2017). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. Journal of Clinical Oncology. 35(15_suppl). e20676–e20676.

Canale, Matteo, Elisabetta Petracci, Angelo Delmonte, et al.. (2016). Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors. Clinical Cancer Research. 23(9). 2195–2202. 196 indexed citations

10.

Ulivi, Paola, Matteo Canale, Elisabetta Petracci, et al.. (2016). Role of TP53 mutations in predicting response to TKI treatment in EGFR-mutated NSCLC patients.. Journal of Clinical Oncology. 34(15_suppl). 9052–9052. 4 indexed citations

11.

Genestreti, Giovenzio, Marcello Tiseo, Hirotsugu Kenmotsu, et al.. (2015). Outcomes of Platinum-Sensitive Small-Cell Lung Cancer Patients Treated With Platinum/Etoposide Rechallenge: A Multi-Institutional Retrospective Analysis. Clinical Lung Cancer. 16(6). e223–e228. 43 indexed citations

12.

Casanova, Cláudia, et al.. (2015). Benefit of eribulin in a patient with HER2 ⁺ breast cancer who progressed after trastuzumab and lapatinib: a case report. Future Oncology. 11(sup15). 9–15.

13.

Genestreti, Giovenzio, Giulio Metro, Hirotsugu Kenmotsu, et al.. (2014). Final outcome results of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: A multi-institutional retrospective analysis.. Journal of Clinical Oncology. 32(15_suppl). 7600–7600. 3 indexed citations

14.

Genestreti, Giovenzio, Luca Ampollini, Marco Angelo Burgio, et al.. (2013). Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone). Annals of Surgical Oncology. 20(9). 2958–2963. 1 indexed citations

15.

Ghi, Maria Grazia, Adriano Paccagnella, Daris Ferrari, et al.. (2013). A phase II-III study comparing concomitant chemoradiotherapy (CRT) versus cetuximab/RT (CET/RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Efficacy results (NCT01086826).. Journal of Clinical Oncology. 31(15_suppl). 6003–6003. 20 indexed citations

16.

Dazzi, Claudio, Anna Cariello, Cláudia Casanova, et al.. (2012). Gemcitabine and Paclitaxel Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Phase II Study. Clinical Lung Cancer. 14(1). 28–33. 12 indexed citations

17.

Ghi, Maria Grazia, Adriano Paccagnella, Daris Ferrari, et al.. (2012). Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2x2 factorial, phase II-III study (NCT01086826).. Journal of Clinical Oncology. 30(15_suppl). 5513–5513. 11 indexed citations

18.

Casanova, Cláudia, et al.. (2003). Tumores vesicales inusuales: carcinoma epidermoide, adenocarcinoma y sarcoma primarios. comportamiento clínico. nuestra experiencia. Actas Urológicas Españolas. 27(2). 123–131. 2 indexed citations

19.

Wüst, J, G Zala, Cláudia Casanova, et al.. (1993). [A trial of modified triple therapy for the eradication of H. pylori in recurrent duodenal ulcer].. PubMed. 123(35). 1645–9. 1 indexed citations

20.

Scheiwiller, Andreas, Cláudia Casanova, A F Muller, et al.. (1992). [Helicobacter pylori colonization of the gastric remnant following partial resection].. PubMed. 122(26). 1015–8. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact